• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:DK200700207U1
    申请号:DK200700207U
    申请日:2007-07-24
    公开日:2007-08-24
    发明作者:Nielsen Lars Arendt；Mohr Asbjoern
    申请人:Euro Celtique Sa；
    IPC主号:
    专利说明:

    DK 2007 00207 U3
    Use of oxycodone for the treatment of visceral pain
    The present invention relates to the treatment of visceral pain.
    There is a continuing need for pain medications that are appropriate to treat visceral pain and especially acute visceral pain effectively. Severe pain in the internal organs is a common cause of medical visits and long-term sick leave in the Western world. The causes of visceral pain can be traced in both organic and functional disorders, but these have in common that complex activation of the nervous system occurs, in many cases the visceral pain is resolved despite the original cause being completely or partially removed. Today, in many cases, morphine is used to treat moderate to severe visceral pain.
    There is also a continuing need for pain medication, which is able to provide very effective pain relief while reducing the risk of unwanted effects. Accordingly, it is highly desirable to provide painkillers which provide very effective pain relief at low doses to avoid or at least reduce unwanted effects and especially the side effects seen at higher doses or in connection with certain specific painkillers.
    Although opioids are increasingly prescribed, knowledge of their effect on visceral pain is limited. However, it is known that in addition to its analgesic effect, morphine can also have a number of undesirable effects, including e.g. respiratory depression, nausea, vomiting, dizziness, mental dizziness, dysphoria, itching, constipation, elevated bile duct pressure, urinary retention and low blood pressure.
    2 DK 2007 00207 U3
    The effect of some active substances on patients can vary widely. Visceral pain is in many ways different from pain in the skin and is often more difficult to treat.
    In the literature, various types of pain associated with diseases of the internal organs are suggested. These types include real or localized visceral pain, visceral referred-pain (radiant pain), localized parietal pain as well as parietal referred-pain pain. In particular, the present invention relates to the treatment of real or localized visceral pain.
    True visceral pain often occurs early in the course of the disease and is peculiar to an undetermined, diffuse, dump, nagging pain, which is localized but tends to radiate. It can be accompanied by a feeling of discomfort and when severe, it causes strong autonomic phenomena such as sweating, vasomotor responses, bradycardia, nausea and vomiting, and sometimes an alarm reaction. It is usually felt in the midline and deep in the body.
    There are a variety of disorders in which visceral pain is experienced. For example, pain related to pancreatitis, veins, pain after abdominal surgery associated with ileus, pain associated with colon irritable syndrome, abdominal pain in non-ulcer dyspepsia or dysmenorrhea. Also, liver pain, kidney pain, epigastric pain, pleural pain as well as painful gallstone colic, pain associated with appendicitis can all be considered visceral pain. Substernal pain or pressure from early myocardial infarction is also visceral. Stomach, duodenum or colon disorders can cause visceral pain. And there are several.
    According to an embodiment of the present invention, it has been found that it is possible to treat moderately to severe visceral pain effectively by administering pain medications comprising opioid oxycodone or pharmaceutically acceptable salts thereof. In addition, it has been found that visceral pain and especially acute {i.e. non-chronic visceral pain can be effectively treated by administering oxycodone at a dose lower than the corresponding dose of other opioids such as morphine. In the following, the present invention relates to a method for effectively treating moderate to severe visceral pain by administering oxycodone at relatively low doses.
    According to one embodiment of the present invention, it has been found that treating visceral pain with a specific dose of oxycodone is more effective than treating the same visceral pain with a higher, similar dose of morphine, while observing almost the same effect if skin or muscle pain be treated by administering similar doses of oxycodone or morphine. In other words, according to the present invention, it has been found that visceral pain and especially acute, moderate to severe visceral pain can be effectively treated by administering oxycodone at relatively low doses, whereas the "corresponding dose" of morphine would be less effective in treating of the same visceral pain. According to the present invention, the "corresponding dose" of morphine does not mean the same quantitative amount of morphine, but refers to the usual equipotent amount of morphine, ie the amount of morphine which usually provides a similar pain relief for the patient. The usual equipotent weight ratio of morphine to oxycodone administration is about 2: 1 (the corresponding mole ratio is about 1.8: 1).
    According to a further embodiment of the present invention, there is provided a method for selectively treating moderate to severe visceral pain in a patient, comprising administering oxycodone in an amount effective to provide pain relief to the patient in need thereof. With the present invention, it is possible for the first time to selectively treat moderate to severe visceral pain, since it was not known before the present generation to treat this specific pain effectively by administering oxycodone at low doses, while other opioids (such as morphine) doses which would have been considered by the person skilled in the art to be equipotent are less effective. According to the present invention, patients suffering only from acute visceral pain will no longer be required to be treated with the opioids commonly used for this purpose (such as morphine, hydromorphone, oxymorphone, codeine and hydrocodone), but by contrast with oxycodone. The present invention thus opens up new therapeutic possibilities for the opioid oxycodone.
    According to a further embodiment of the invention, there is provided a method of treating moderate to severe visceral pain in a patient already treated with morphine or a salt, the method comprising: (a) discontinuing the morphine treatment; and (b) administering oxycodone or a salt thereof in an amount less than 50% by weight of the morphine or salt thereof.
    According to a further embodiment, there is provided a method for treating moderate to severe pain in a patient already treated with hydromorphone, oxymorphone, codeine, hydrocodone or salts thereof, comprising: (a) discontinuing treatment with hydromorphone, oxymorphone , codeine, hydrocodone or salts thereof; and (b) administering oxycodone or a salt thereof in an amount less than the equipotent amount of hydromorphone, oxymorphone, codeine, hydrocodone or salts thereof.
    According to one embodiment of the present invention, it is possible to treat acute visceral pain by administering oxycodone at a dose sufficiently low to reduce or avoid unwanted side effects. This means that the therapeutic levels can be achieved without or with fewer side effects, such as e.g. nausea, vomiting, constipation and drowsiness that can be associated with high levels of oxycodone in the blood.
    The recognition that visceral pain can be effectively treated at low doses of oxycodone makes it possible to use immediate-release formulations and depot-release formulations. According to the present invention, it may be preferable to treat visceral pain and especially acute visceral pain by administering oxycodone-containing dosage forms for use once daily, twice daily, three times daily or four times daily. According to the present invention, it may be particularly preferred to use oxycodone-containing depot formulations where the dose does not exceed 40 mg of oxycodone, preferably does not exceed 30 mg of oxycodone, and further preferably does not exceed 10 mg of oxycodone. According to the present invention, it may be most preferred to use oxycodone-containing depot formulations and preferably dosage forms for once-daily, twice-daily, 3-daily or 4-daily doses containing about 1%. 10 mg, approx. 9 mg, approx. 8 mg, approx. 7 mg, approx. 6 mg or approx. 5 mg oxycodone. It is also preferred in some embodiments to use single units of oxycodone or salts thereof, e.g. oxycodone or salts thereof without the addition of APAP or other active substances.
    The present invention relates to the treatment of visceral pain, including pancreatitis, veins, pain following abdominal surgery associated with ileus, pain associated with colon irritable syndrome, abdominal pain in non-ulcer dyspepsia or dysmenorrhea, liver pain, renal pain, epigastric pain, pleural pain as well as painful gallstone colic as well as pain associated with appendicitis by administering pain medication including oxycodone alone or in combination with other active substances and especially other painkillers. In addition, the present invention relates to the treatment of visceral pain resulting from gastric, duodenal or colon disorders, Crohn's syndrome, gallbladder pain, severe menstrual pain and certain post-operative pain conditions. The present invention also relates to the treatment of moderate, moderately severe and / or severe visceral pain.
    Preferably, the dosage form to be treated to treat visceral pain according to the present invention is an oral dosage form, such as a tablet or capsule, with it also being a pill or other solid or liquid dosage form which can be administered orally, via implant, parenteral, sublingual or rectal. Preferably, the formulation according to the present invention is an oral tablet, capsule or any other suitable oral unit dosage form.
    According to the present invention, visceral pain can be treated by administering oxycodone or a pharmaceutically acceptable salt thereof. The term "pharmaceutically acceptable salt" includes, but is not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, Ν, Ν'-dibenzynethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and the like; organic salts such as formate, acetate, trifluoroacetate, maleate, fumarate, tartrate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; amino acid salts such as arginate, asparginate, glutamate and the like.
    The oxycodone-containing formulations which are suitable for treating visceral pain in accordance with the present invention may be immediate or depot delivery formulations. It is preferable to use depot formulations to treat visceral pain, and it may be particularly advantageous to administer dosage forms containing oxycodone for use once daily, twice daily, three times daily or four times daily.
    7 DK 2007 00207 U3
    According to some embodiments, such an oral dosage form comprises a depot material which is incorporated into a matrix together with the oxycodone or pharmaceutically acceptable salt thereof to provide the depot release of oxycodone. The deposit may be hydrophobic or hydrophilic as desired. The oral dosage form can be prepared as granules, spheroids, matrix multiparticles, etc., comprising oxycodone or a pharmaceutically acceptable salt thereof in a depot matrix which can be compressed to form a tablet or encapsulated. The oral dosage form may optionally comprise other pharmaceutically acceptable ingredients (e.g., diluents, binders, dyes, lubricants, etc.).
    A non-limiting list of depot release materials which may be included in a depot matrix for a dosage form that can be used to treat visceral pain in accordance with the present invention comprises hydrophilic and / or hydrophobic materials such as gums, cellulose seethers, acrylic resins, protein-derived materials, waxes, shellac, and oils, such as hydrogenated castor oil and hydrogenated vegetable oil. However, any pharmaceutically acceptable, hydrophobic or hydrophilic depot material capable of providing depot release of oxycodone or the pharmaceutically acceptable salt thereof can be used in accordance with the present invention. Preferred depot polymers include alkyl celluloses such as ethyl cellulose, acrylic and methacrylic acid polymers and copolymers; and cellulose ethers, especially hydroxylalkylcelluloses (especially hydroxypropylmethylcellulose) and carboxyalkylcelluloses. Preferred acrylic and methacrylic acid polymers and copolymers include methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylates, ethyl acrylate, trimethylammonioethyl methacrylate, cyanethyl methacrylate, aminalkyl methacrylate copolymer, poly (acrylic acid) poly (acrylic acid) anhydride), poly (methacrylate, poly (methacrylic anhydride), and glycidyl methacrylate copolymers).
    Oxycodone-containing formulations which can be used to treat visceral pain in accordance with the present invention are e.g. disclosed in WO 02/087512 and EP 0 576 643, both of which are incorporated herein by reference.
    EP 0 576 643 relates to solid dosage form in controlled release, which dosage form comprises a therapeutically effective amount of oxycodone or a salt thereof in a matrix.
    The oral dosage forms described in EP 0 576 643 may be particularly suitable for the present invention. Dosage forms according to EP 0 576 643 include formulations for use "twice daily". The oral dosage forms may be in the form of e.g. granules, spheroids or pellets in a capsule or any other suitable solid form.
    According to the present invention, it may be preferred that the oral dosage form contains between 1 and 50 mg, preferably between 1 and 15 mg, more preferably between 5 and 10 mg, and more preferably about 5 mg. 5 mg oxycodone hydrochloride. Alternatively, the dosage form may contain the same or molar equivalent amounts of other oxycodone salts or of the oxycodone base.
    The matrix of the dosage form to be used to treat visceral pain in accordance with the present invention may preferably be a controlled release matrix, although normal release matrices having a drug controlling release delivery may also be used. . Suitable materials for inclusion in a controlled release matrix include U 2007 g (a) hydrophilic polymers such as rubber types, cellulose ethers, acrylic resins and protein-derived materials. Of these polymers, the cellulose ethers are preferred, especially hydroxyalkyl celluloses and carboxyalkyl celluloses. The dosage form may contain between 1% and 80% (by weight) of at least one hydrophilic or hydrophobic polymer.
    (b) Digestible, long-chain (C8-C50, especially C12-C4)), substituted or unsubstituted hydrocarbons such as fatty acids, fatty alcohols, glycerine esters of fatty acids, mineral and vegetable oils and waxes. Hydrocarbons having a melting point of between 25 ° C and 90 ° C are preferred. Of these long chain hydrocarbon materials, fatty (aliphatic) alcohols are preferred. The dosage form may contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.
    (c) polyalkylene glycols. The dosage form may contain up to 60% (by weight) of at least one polyalkylene glycol.
    A particularly convenient matrix comprises at least one water-soluble hydroxyalkyl cellulose, at least one C12-C36, preferably C14-C22, aliphatic alcohol and optionally at least one polyalkylene glycol.
    The at least one hydroxyalkylcellulose may preferably be a hydroxy (C1-C6) alkylcellulose such as hydroxypropylcellulose, hydroxypropylmethylcellulose and especially hydroxyethylcellulose. The amount of the at least one hydroxyalkyl cellulose in the oral dosage form will ia. be determined by exactly what release rate of oxycodone is required. Preferably, however, the oral dosage form contains between 5% and 25%, especially between 6.25% and 15% (by weight) of the at least one hydroxyalkyl cellulose.
    The at least one aliphatic alcohol may e.g. be lauryl alcohol, myristyl alcohol or stearyl alcohol. However, according to particularly preferred embodiments, the at least one aliphatic alcohol is ethyl alcohol or cetostearyl alcohol. The amount of at least one aliphatic alcohol in an oral dosage form will be determined by exactly what oxycodone release rate is required.
    According to a further preferred embodiment, the controlled release composition may contain from ca. 5 to approx. 25% acrylic resin and from approx. 8 to approx. 40% by weight of aliphatic alcohol relative to the weight of the total dosage form. A particularly preferred acrylic resin comprises Eudragit® RS 30D, which is commercially available from Rohm Pharma.
    In addition to the above ingredients, a controlled release matrix may also contain appropriate amounts of other materials, e.g. diluents, lubricants, binders, granulating aids, dyes, flavors and lubricants, which are traditional ingredients in the pharmaceutical field.
    As an alternative to a controlled release matrix, the dosage form to be used to treat visceral pain may include a normal release matrix having a layer controlling the delivery of the drug. According to particularly preferred embodiments of this aspect of the preparation, the dosage forms may comprise film-coated spheroids containing active ingredient and a non-water-soluble spheronizing agent. The term "spheroid" is known in the art and refers to a spherical granule having a diameter of between 0.5 and 2.5 mm, especially between 0.5 and 2 mm. Details of film-coated spheroids and preparation of the above dosage forms are also disclosed in EP 0 576 643, which is incorporated herein by reference.
    Oxycodone-containing controlled release formulations which may be particularly suitable for treating visceral pain in accordance with the present invention may include oxycodone hydrochloride, lactose (spray dried), Povidone, Eudaragit® RS 30 D (solids), ®, steary alcohol, talc and magnesium stearate.
    Further depot release formulations containing oxycodone and suitable for treating visceral pain in accordance with the present invention are disclosed in WO 02/087512, incorporated herein by reference.
    According to the present invention, it may be preferable to use a dosage form which stably provides an analgesic effect for at least approx. 24 hours after oral administration; and which dosage form provides an average C24 / Cmax oxycodone ratio of 0.6: 1.0 after stable oral administration to the patients. In some embodiments of the preparation, the dosage form, after administration to patients, may provide an average Tmax of oxycodone in vivo, occurring after between ca. 2 to 17 hours (e.g., between about 2 hours and about 8 hours) after stable dosage form administration. The term "average" as used in the present invention and when used to define a pharmacokinetic value (e.g., Tmax) represents the arithmetic average value measured over a patient population. In some embodiments, it may average Tmax for oxycodone in vivo occurs at between about 6.5 hours and about 17 hours, at between about 8 and about 16 hours, at between about 10 and about 16 hours, or at between about 12 hours to about 16 hours after the steady state administration of the dosage form, the term "steady state" means that the amount of drug entering the system is approximately the same as the amount of drug leaving the system. "steady state" eliminates the drug at approximately the same rate as the drug becomes available to the patient's system through absorption into the bloodstream.
    In some embodiments, the oral dispensing dosage forms which may be used to treat visceral pain in accordance with the present invention comprise a matrix comprising a depot release material and oxycodone or a pharmaceutically acceptable salt thereof. In some embodiments, the matrix is compressed into a tablet and may be optionally coated with a coating which, in addition to the depot release material in the matrix, can control the release of oxycodone or the pharmaceutically acceptable salt thereof from the formulation so that blood levels of the active substance are maintained within the therapeutic range. a longer period of time. According to some alternative embodiments, the matrix can be encapsulated.
    According to some embodiments, the oral dispensing dosage form to be used in accordance with the present invention may be an osmotic dosage form comprising a single layer or a bilayer core comprising oxycodone or a pharmaceutically acceptable salt thereof; an expandable polymer; a semipermeable membrane surrounding the nucleus, as well as a channel disposed in the semipermeable membrane for the delivery of oxycodone or a pharmaceutically acceptable salt thereof, so that blood levels of the active substance are maintained within the therapeutic range for a prolonged period when administered to patients.
    According to some embodiments, the oral dosage form of depot delivery to be used in accordance with the present invention may comprise a substantially homogeneous core comprising oxycodone or a pharmaceutically acceptable salt thereof; and an expandable polymer; a semipermeable membrane surrounding the core; and a channel disposed in the semipermeable membrane for the delivery of oxycodone or a pharmaceutically acceptable salt thereof, so that blood levels of the active substance are maintained within the therapeutic range for a prolonged period when administered to patients.
    13 DK 2007 00207 U3
    Another analgesic oral dosage form of administration which may be suitable for use in accordance with the present invention is disclosed in EP 1 449 531, which is incorporated herein by reference. The dosage form comprises a combination of a pharmaceutical extrudate, in the form of multiparticles comprising 5 mg to 400 mg of oxycodone or a salt thereof dispersed in a matrix. EP 1 449 531 also relates in part to novel melt-extruded oral dosage forms with depot release comprising a pharmaceutically acceptable hydrophobic material, an inhibitor selected from waxes, fatty alcohols and fatty acids, and a drug. The extrudate may be divided into unit doses of the opioid analgesic. The unit doses of multiparticles may then be incorporated into a solid pharmaceutical dosage formulation, e.g. by compression or molding into tablets, by placing a necessary amount in a gelatin capsule or by shaping the extruded product into a suppository.
    Additional controlled release matrices or controlled release dosage forms which may be suitable according to the present invention are described in the following documents.
    EP 0 548 448, incorporated herein by reference, refers to a stabilized, controlled release dosage form having a coating derived from an aqueous dispersion of ethyl cellulose obtained by coating a substrate comprising a therapeutically active substance with an aqueous dispersion of ethyl cellulose and then cure the coated substrate at a temperature and relative humidity raised to an appropriate level under ambient conditions until the coated dosage form achieves a stabilized solution profile which is substantially unaffected by exposure to the storage conditions with elevated temperature and / or elevated relative humidity.
    14 DK 2007 00207 U3 EP 0 531 611 is incorporated herein by reference and relates to a controlled release dosage form having a matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and an appropriate suppository base. In addition, when the composition is to be administered orally, the matrix comprises a higher aliphatic alcohol.
    EP 0 553 392, EP 0 630 646 and EP 0 636 366 relate to controlled release dosage forms which include certain coatings. EP 0 647 448 and EP 698 389 also relate to orally administrable opioid formulations which provide controlled or depot release of the active substance. All said documents are incorporated herein by reference.
    Opioid formulations, administered once daily and with depot dispensing, are described in U.S. Patent No. 5,478,577; 5,672,360; 5,958,459; 6,103,261; 6,143,322; 5,965,161; 5,958,452 and 5,968,551, all of which are incorporated herein by reference.
    In addition, commercially available oxycodone-containing oral preparations are also available which can be used to treat visceral pain in accordance with the present invention. These commercially available oxycodone-containing preparations include Oxynorm® (immediate release preparation) and OxyContin®. OxyContin is a controlled release pain reliever commercially available from Purdue Pharma L.P .. OxyContin® is available in dosage strengths of 10 mg, 20 mg, 40 mg and 80 mg. OxyContin is also commercially available in the UK through Napp Pharmaceuticals at a dosage of 5 mg. According to the present invention, low dose preparations may be preferred. Dosage forms with an OxyContin®-like matrix and comprising ca. 5 mg of oxycodone hydrochloride is particularly preferred.
    15 DK 2007 00207 U3
    It may be preferable, in accordance with the present application, to provide a dosage form comprising a combination of opioid agonist and opioid antagonist to reduce or prevent its abuse potential. Suitable dosage forms comprising combinations of opioid agonists and opioid antagonists are described, e.g. in WO 99/32119, WO 99/32120, WO 01/58447, WO 03/013479 and WO 03/013476.
    Subsequently, various aspects of the present invention are referred to. However, it will be understood that the present invention is not limited to such aspects.
    It will be understood that for the purposes of the present invention, the following terms have the following meanings:
    The term "visceral pain" in the context of the present invention is defined as referring to pain in the viscera of the human body and in particular to pain arising from the internal organs.
    The term "acute visceral pain" in the context of the present invention is defined as referring to non-chronic visceral pain.
    The term "effective" in relation to the analgesic effect is defined in connection with the present invention as a satisfactory reduction or removal of pain, combined with a course of tolerable level of side effects, as determined by the patient, being a human.
    The term "treat selectively" as used in the present invention is defined as the selective use of oxycodone to treat a specific pain, namely acute, visceral pain, effectively. Treating visceral pain with, for example, morphine would also cause some pain relief effect, but would not be considered to be "selective" as such an analgesic effect would be significantly lower compared to oxy-codon and would also be observable for other pain. In other words, no selective effect could be observed when visceral pain is treated with morphine.
    5
    The present invention encompasses the following aspects:
    According to one aspect of the present invention, there is provided a method of effectively treating visceral pain which comprises administering oxycodone at a dose sufficiently low to reduce or avoid desired side effects.
    According to a further aspect of the present invention, there is provided a method of effectively treating visceral pain which comprises administering an oxycodone-containing dosage form, the dosage form providing immediate delivery or depot delivery of oxycodone.
    According to a further aspect of the present invention, there is provided a method of effectively treating visceral pain, which comprises administering oxycodone at a dose which provides a significantly better effect than the oral equipotent dose of morphine or other opioid, wherein the equipotene refers to the treatment of skin and muscle pain.
    According to a further aspect of the present invention, there is provided a method for selectively treating acute visceral pain in a patient which comprises oral administration of oxycodone in an effective amount to provide pain relief to a patient in need thereof.
    According to a further embodiment of the present invention, there is provided a method for treating moderate to severe visceral pain in a patient already treated orally with morphine or a salt thereof, the method comprising: (a) discontinuing oral morphine treatment; and (b) administering oxycodone or a salt thereof orally and in an amount of less than 50% by weight of the morphine or salt thereof. It may be preferred to administer oxycodone orally and in an amount of less than 45% by weight, preferably below 40% by weight, more preferably below 35% by weight, even more preferably below 30% by weight, and most preferably 25% by weight of the morphine or salt thereof. .
    In addition, the present invention comprises the following aspects:
    Method of treating acute visceral pain by administering oxycodone at a dose lower than the corresponding dose of morphine required to provide the same therapeutic effect.
    Method of treating visceral pain by administering oxycodone at a dose lower than the corresponding dose of morphine required to treat the same visceral pain just as effectively.
    Method of treating visceral pain effectively by administering oxycodone orally at a dose lower than the equipotent dose of oral morphine, the equipotency referring to the treatment of skin and muscle pain. The weight ratio of said oxycodone dose to said morphine dose is preferably less than 1: 2, more preferably less than 1: 2.5; even more preferably less than 1: 3, most preferably less than 1: 4.
    Use of oxycodone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of visceral pain.
    18 DK 2007 00207 U3
    Use of oxycodone or a pharmaceutically acceptable salt thereof, wherein oxycodone or a pharmaceutically acceptable salt thereof is used in the manufacture of a medicament for the treatment of acute visceral pain.
    Use of oxycodone or a pharmaceutically acceptable salt thereof, wherein oxycodone or a pharmaceutically acceptable salt thereof is used in the manufacture of a medicament for the selective treatment of visceral pain.
    Use of oxycodone or a pharmaceutically acceptable salt thereof, wherein the drug is an oral dosage form containing oxycodone or a pharmaceutically acceptable salt thereof.
    Use of an oral controlled dosage form for the manufacture of a medicament for controlling visceral pain in human subjects, the controlled release oral dosage form comprising: a) from 5 mg to 80 mg oxycodone or a salt thereof; b) an effective amount of an acrylic resin matrix, which acrylic resin matrix is selected such that the formulation provides substantially pH-independent in vitro dissolution characteristics; C) a pharmaceutical diluent.
    According to the present invention, the term "substantially pH independent" indicates that the difference at any given time between the amount of oxycodone delivered at a pH of 1.2 and the amount delivered at a pH of 7.5 (when measured in vitro using the USP-Basket method at 100 rpm in 900 ml aqueous buffer solution), 15%, preferably 10% (by weight based on the total amount of oxycodone or salts thereof in the dose ring storm) or less.
    19 DK 2007 00207 U3
    Use of a controlled release oral dosage formulation for the manufacture of a medicament for controlling visceral pain in a human subject, the controlled release oral dosage form comprising: Oxycodone or a salt thereof; b) an effective amount of a controlled release acrylic resin matrix, which acrylic resin matrix is selected such that the formulation provides substantially pH-independent in vitro dissolution characteristics; and c) a pharmaceutical diluent.
    Further aspects are described in the claims.
    According to a further aspect of the preparation, there is provided a method of treating moderate to severe visceral pain in a patient, which comprises repetitively: administering 5 mg of oxycodone with depot twice daily, three times daily or four times daily.
    According to a further aspect of the present invention, there is provided a method of treating moderate to severe visceral pain in a patient, which comprises repeating once daily administration of 10 mg oxycodone with depot.
    It will be appreciated that the following aspects of the present invention may be specific or preferred embodiments of the foregoing aspects of the present invention:
    Also according to the present invention, it may be preferred that the oxycodone-containing drug is in the form of a solid oral dosage form such as a tablet or capsule.
    20 DK 2007 00207 U3
    According to the present invention, it may be preferred that the oxycodone-containing oral dosage form provides for immediate release of oxycodone.
    According to the present invention, it may be preferred that the oxycodone-containing oral dosage form provides for the delivery of oxycodone.
    According to the present invention, it is preferable that the oxycodone-containing dosage form with depot delivery be administered orally either once daily or twice daily.
    According to the present invention, it may be preferred that the oxycodone-containing drug comprises oxycodone in an amount of from ca. 1 mg to approx. 50mg, preferably between 1 and 15mg, more preferably between 5mg and 10mg and most preferably about 5 mg or an equivalent amount of a pharmaceutically acceptable salt thereof. If the oxycodone-containing drug is in the form of a once-daily or twice-daily dosing formulation, the amount of oxycodone may in some cases be higher and may be within the range of approx. 5 mg to approx. 160 mg, but preferably does not exceed 40 mg, more preferably does not exceed 20 mg, and most preferably does not exceed 10 mg.
    According to a further aspect of the preparation, there is provided a method for treating moderate to severe visceral pain in a patient, comprising: (a) administering to a patient a human, a unit dose containing oxycodone or a salt thereof in an amount of 5 mg; (b) monitoring the pharmacodynamic parameters triggered by the unit dose in the human patient and determining whether the pharmacodynamic parameters are appropriate to continue the treatment of the patient concerned on a repeated basis; (C) titrating the patient by adjusting the dose of oxycodone or a salt thereof given to the patient by administering a unit dose of oxycodone or a salt thereof with a different amount of oxycodone or a salt thereof if it is determined that the pharmacodynamic parameters are not satisfactory or to maintain the dose of oxycodone or a salt thereof in the unit dose at a previously administered amount, if the pharmacodynamic parameters are deemed appropriate; (d) continuing the step (c) titrating by adjusting the dose of oxycodone or a salt thereof until appropriate stable pharmacodynamic parameters are obtained in the patient; and (e) continuing to administer the dose of oxycodone or a salt thereof until the treatment is completed. It is preferred that the patient be titrated with a unit dose containing oxycodone or a salt thereof in an amount of from 5 mg to 10 mg.
    According to further embodiments of the present invention, the oxycodone-containing drug may contain another active ingredient, preferably another opioid or non-opioid analgesic. Preferred combinations of oxycodone and other active ingredients are described above.
    Forsøasevidens
    The above is also supported by the experimental evidence referred to below.
    The experimental studies referred to below are based on a comparison of different preparations applied to healthy volunteers by inflicting these experimental pain, providing in clinical trials insufficient information, on the one hand, because there is a large difference in patients, and because most diseases cause many symptoms other than pain that affect the assessment of how effective the pain relief is. Excessive pain can be inflicted on healthy volunteers under controlled conditions, thus avoiding such misrepresentation. However, several experimental stimuli are needed to simulate the complex clinical situation. It is also necessary to use different opioids to obtain adequate, differentiated knowledge of deep pain on different pain mechanisms, and to assess the clinical efficacy of opioids. To examine the efficacy of the various opioids for the treatment of visceral pain, a standard test battery of skin, muscle and visceral stimuli was applied. Blood samples were taken to determine the opioid concentration in plasma.
    In recent years, methods have been developed whereby deep and visceral stimuli can be reproducibly applied. These methods allow activation of the pain system with different stimuli with the possibility to activate different types of nerve pathways in the same experiment. In the experiment described herein, a comparison was made of the efficacy of different opioids on different types of stimuli on the skin, muscles and intestines of healthy volunteers. Skin and muscle pain was inflicted by pressure, current and temperature (on the skin only). Stimulation of the internal organs was also achieved by the use of pressure via a balloon placed at the bottom of the esophagus. The balloon can be played out and produce mechanical stimuli that are experienced as mild pain / discomfort. In addition, cold and heat stimuli can be applied by passing water at different temperatures through the balloon.
    Purpose
    The purpose of the present study was to compare the efficacy of two different opioids on different experimental pain models, where the pain inflicted is very similar to clinical pain. Therefore, the painfully applied pain must activate various peripheral deep / visceral pain pathways in several organs under controlled conditions. During the trial, the pain intensity was subsequently measured as a result of a well-defined pain stimulus, but the analgesic effect of orally administered opioid is built up according to the process diagram below:
    Flow
    Expected clinical efficacy of orally administered opioid *
    0 30 ~ 60 90 min ~ ^ t t i t pain test pain test pain test pain test * supported by plasma analyzes of the opioids and knowledge of their distribution between plasma and CNS.
    Each of the experiments was conducted on healthy volunteers and included 24 individuals aged 18 to 65, male to female ratio 1: 1, with no previous pain-causing chronic or recurrent disease. The subjects also underwent a physical examination and were screened for diseases by urine examination (dipsticks for measuring protein and sugar) as well as blood samples (hemoglobin, C-reactive protein, plates, leukocytes, creatinine, aspartate aminotransferase, alkaline phosphatase, prothrombin). -time) before being included in the experiment. The duration of each of the partial trials is a maximum of two hours. Subjects were enrolled three times with at least one week between each trial.
    24 DK 2007 00207 U3
    Experimental Design and Methods In the experimental series, morphine was compared with oxycodone. Furthermore, both preparations are compared with a placebo. The preparations were tested using experimental pain models, including skin, intramuscular visceral pain simulation of healthy subjects.
    The experiments were performed in accordance with a block randomized (three blocks), balanced (opioid sequence), double-blind, three-arm placebo-controlled cross-over design (opioids and placebo) and open treatment control. The blindness to the patients was ensured by pouring the medicine with grape juice (to ensure blindness to the placebo) according to the pattern below.
    Opiod Placebo mg Morphine 30 mg Oxycodone 15 mg 100 ml grape juice 15 ml morphine DAK oral solution 2 mg / ml + 85 ml grape juice 15 ml Oxynorm oral solution 1 mg / ml + 85 ml grape juice
    At least seven days elapsed between each dose to ensure adequate leaching.
    Experimental pain models / pain stimuli
    Several separate experiments were performed, where placebo and the two opioids were tested on the experimental pain models. Prior to that, a test was performed in which the individuals had tested the various pain stimuli and had learned to rate them on the scales used (intensity and radiated spread of pain). Pain stimuli were given before and during treatment (at the expected maximum effect of the preparation). The model was first tested on skin, muscle and esophageal stimuli. Skin, muscle, and visceral stimulus stimuli were applied at the different intensities for which the trial was to test, after 30, 60, and 90 minutes.
    The effect of opioids on mechanical stimuli was investigated by stimulating the skin and muscle with a pressure altimeter (Somedia algometer) and by stimulating the esophagus with a balloon in which the cross-sectional area can be calculated (impedance planimetry). Sensitivity to electrical stimuli was examined on the skin and muscles of the forearm ("single and repetitive stimuli"), thus ensuring that both pure peripheral and central mechanisms ("repetitive stimuli") were examined. The effect on heat stimuli was measured on the skin of the forearm (Somedic thermo test) and in the esophagus with hot and cold water running through the balloon. A stimulus response curve was generated for all types of stimuli. Pain intensity was rated on a visual analogue scale (VAS) from 0 (no pain) to 10 (unbearable), combining non-painful (0-4.9 on the scale) and painful (5-10 on the scale) stimuli. Stimuli with an intensity of 1, 3, 5 = pain detection threshold and 7 = moderate pain were indicated.
    kinetics
    Blood samples of 10 ml to assess the variation in plasma concentration of opioids were taken from a peripheral venflon for the opioid dose (blank) and at 30, 45, 60, 90 and 120 minutes after dosing. Therefore, a total of 240 ml of blood was taken throughout the trial (four weeks).
    Preparations and dose
    Morphine DAK oral solution 2 mg / ml; dose of 30 mg Oxynorm oral solution 1 mg / m; dose of 15 mg.
    It is assumed that the equipotent ratio of morphine to oxycodone is approx. 2: 1 in weight.
    Statistical processing of data 26 DK 2007 00207 U3
    The pain threshold was determined for the different stimuli before the trial and after 30 minutes (expected initial effect), 60 and 90 minutes (expected maximum effect). Stimuli were produced at different intensities for stimulation on the skin, muscles and esophagus. Data is stored electronically and loaded into CRFs. The analgesic effect before and during the trial was determined by two-sided analysis of variance with the factors 1) either placebo against morphine or morphine against oxycodone, and 2) intensity or pain stimulus and the dependent variable "pain assessment". The effect on pain quality was investigated using the Danish version of " McGill Pain Questionnaire ”, which was filled with maximum pain.
    The effect on the pain threshold after 90 minutes is counted as the primary endpoint. The other data (effect on other pain intensities, change in qualitative descriptive words, change in specified pain range) were considered to be secondary descriptive variables. Thus, the plasma measurements should be considered as secondary endpoints used in the descriptive phase to support the effect on pain data.
    Results On the skin, both opioids, morphine and oxycodone, had significantly greater analgesic effect than placebo and there was no significant difference between morphine and oxycodone for any of the modalities investigated (see Figure 1). It is also noted that the 2: 1 potency ratio (oxycodone: morphine) was confirmed in this study as being "equipotent" with respect to skin pain.
    In muscle, the opioids again had significantly greater analgesic effect than placebo, and there was no significant difference between morphine and oxycodone for any of the modalities investigated (see Fig. 1 It is also noted that the potency ratio of 2: 1 (oxycodone: morphine) was confirmed in this study as being "equipotent" in relation to muscle pain.
    In the viscera (here the esophagus), a significantly better analgesic effect for oxycodone compared to mechanical stimulation (via balloon enlargement) was observed in comparison with morphine and placebo (see Fig. 2). However, morphine also provided some analgesic effect (compared to placebo).
    There was also significantly greater pain relief with oxycodone by pain stimulation with heat (via hot water in the balloon) compared to morphine and placebo (see Figure 2). However, morphine also provided some analgesic effect (compared to placebo).
    The above results clearly confirm that visceral pain and especially acute visceral pain can be treated effectively and selectively by administering oxycodone at a dose lower than the corresponding one, ie. equipotent dose of other opioids such as morphine.
    As preferred embodiments of the invention have been described in detail, it will be understood that the creation as defined by the above paragraph is not to be considered as being limited to specific details as set forth in the foregoing description, many obvious variations thereof being obvious without departing from the foregoing. from the spirit and scope of the present invention.
    All of the documents cited or cited herein ("documents cited herein"), including any instructions, descriptions, product specifications from manufacturers, are hereby incorporated herein by reference and may be used in the practice of making them. Citing or identifying any document in this application should not be construed as admitting that such document is available as prior art in relation to the present disclosure. It should be noted that in this specification, glosses such as "encompassing", "encompassing", "encompassing" and the like may have the meaning assigned to them by US patent law, for example: "includes", "included in", "including" and the like.
    权利要求:
    Claims (20)
    [1]
    Use of oxycodone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of visceral pain.
    [2]
    Use according to claim 1, wherein oxycodone or a pharmaceutically acceptable salt thereof is used in the manufacture of a medicament for the treatment of acute visceral pain.
    [3]
    Use according to any one of claims 1 or 2, wherein oxycodone or a pharmaceutically acceptable salt thereof is used in the manufacture of a medicament for the selective treatment of visceral pain.
    [4]
    Use according to any one of the preceding claims, wherein the medicament is an oral dosage form containing oxycodone or a pharmaceutically acceptable salt thereof.
    [5]
    Use according to any one of the preceding claims, wherein the visceral pain is pain associated with pancreatitis, veins, pain after abdominal surgery in connection with ileus, pain in connection with the irreversible colonic syndrome, abdominal pain in non- ulcer dyspepsia or dysmenorrhea, liver pain, kidney pain, epigastric pain, pleural pain as well as painful gallstone colic, appendicitis pain.
    [6]
    Use according to any one of the preceding claims, wherein the visceral pain results from gastric, duodenal or colon disorders, from Crohn's syndrome, gallbladder pain, severe menstrual pain or similar post-operative pain conditions.
    [7]
    Use according to any one of the preceding claims, wherein the medicament is a dosage form for use once daily, twice daily, three times daily or four times daily containing oxycodone or a pharmaceutically acceptable salt thereof.
    [8]
    Use according to any one of the preceding claims, wherein the medicament is a once-daily dosage form containing oxycodone or a pharmaceutically acceptable salt thereof in an amount of approx. 10 mg.
    [9]
    Use according to any one of the preceding claims, wherein the medicament is a twice daily dosage form containing oxycodone or a pharmaceutically acceptable salt thereof in an amount of 5 mg.
    [10]
    Use according to any one of the preceding claims, wherein the medicament is a dosage form for administration three times daily containing oxycodone or a pharmaceutically acceptable salt thereof in an amount of approx. 5 mg.
    [11]
    Use according to any one of the preceding claims, wherein the medicament is a dosage form for administration four times daily containing oxycodone or a pharmaceutically acceptable salt thereof in an amount of 5 mg.
    [12]
    Use according to any one of the preceding claims, wherein the medicament is a dosage form with a depot release containing not more than 40 mg of oxycodone or a pharmaceutically acceptable salt thereof, preferably not more than 30 mg of oxycodone or a pharmaceutically acceptable salt thereof. and further preferably not more than 10 mg of oxycodone or a pharmaceutically acceptable salt thereof.
    [13]
    Use according to any one of the preceding claims, wherein the medicament is a single unit formulation. 31 DK 2007 00207 U3
    [14]
    Use according to any one of the preceding claims, wherein the medicament is an oral dosage form containing oxycodone or a pharmaceutically acceptable salt thereof, at a dose lower than the corresponding dose of morphine required to provide the same therapeutic effect.
    [15]
    Use according to any one of the preceding claims, wherein the medicament is an oral dosage form containing oxycodone or a pharmaceutically acceptable salt thereof in a dose which provides a significantly better effect than the oral equipotent dose of morphine, to which the equipotene refers. for the treatment of skin and muscle pain.
    [16]
    Use according to any one of the preceding claims, wherein oxycodone or its pharmaceutically acceptable salt is administered at a dose lower than the oral equipotent dose of morphine, the equipotency referring to the treatment of skin and muscle pain.
    [17]
    The use of claim 16, wherein the ratio of said oxycodone dose to said morphine dose is less than 1: 2, preferably less than 1: 2.5; more preferably less than 1: 3, most preferably less than 1: 4.
    [18]
    Use according to any one of claims 1 to 6, wherein the medicament is a controlled release oral dosage form for controlling visceral pain in human patients, the dosage form comprising: a) from 5 mg to 80 mg oxycodone or a salt thereof; b) an effective amount of a controlled release acrylic resin matrix, which acrylic resin matrix is selected such that the formulation provides substantially pH-independent in vitro dissolution characteristics; c) a pharmaceutical diluent.
    [19]
    Use of oxycodone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating visceral pain in a patient, who is already orally treated with morphine or a salt thereof, wherein oxycodone or a pharmaceutically acceptable salt thereof is administered. orally in an amount less than 50% by weight of the morphine or its salt after the oral treatment with morphine is discontinued. 5
    [20]
    Use according to claim 19, wherein oxycodone or a pharmaceutically acceptable salt thereof is administered orally and in an amount of less than 45% by weight of the morphine or salt thereof, preferably below 40% by weight, more preferably below 35% by weight, even more preferably below 30% by weight and most preferably 10% by weight of the morphine or salt thereof.
    类似技术:
    公开号 | 公开日 | 专利标题
    DK200700207U3|2007-09-28|Use of oxycodone for the treatment of visceral pain
    CN104958282B|2018-05-29|Tapentadol hydrochloride composition
    ES2758831T3|2020-05-06|Powerful new dosage forms of tapentadol
    DK200000364U3|2001-03-23|Controlled release oxycode preparations
    JP2008517970A|2008-05-29|Delayed dosage form of drug for treatment of insomnia
    JP2009527477A|2009-07-30|Low flush niacin formulation
    EA030310B1|2018-07-31|Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
    Patil et al.2011|Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time
    Joshi et al.2011|Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time
    Sagivenkatasita2012|Formulation and Evaluation of Extended Release Tablet of Oxybutynin Hydrochloride.
    TW200816997A|2008-04-16|Treatment of pain
    同族专利:
    公开号 | 公开日
    IL184530D0|2007-10-31|
    SI1838318T1|2010-02-26|
    CA2595043C|2013-11-19|
    AU2006207498A1|2006-07-27|
    ME01066B|2012-10-20|
    CA2595043A1|2006-07-27|
    PL1838318T3|2010-03-31|
    MY144471A|2011-09-30|
    TW200637554A|2006-11-01|
    HK1107933A1|2008-04-25|
    HRP20090679T1|2010-01-31|
    EP1838318A1|2007-10-03|
    JP5049139B2|2012-10-17|
    CY1109660T1|2014-08-13|
    JP2008526927A|2008-07-24|
    UA85471C2|2009-01-26|
    AU2006207498B2|2009-11-19|
    US20080200493A1|2008-08-21|
    TWI432196B|2014-04-01|
    EP1838318B1|2009-10-21|
    KR20140091782A|2014-07-22|
    KR20170021905A|2017-02-28|
    MX2007007207A|2007-08-15|
    CN101106996B|2013-10-23|
    NO338968B1|2016-11-07|
    NZ555852A|2010-01-29|
    DK1838318T3|2010-01-04|
    AT9895U1|2008-05-15|
    ES2333901T3|2010-03-02|
    KR20190135557A|2019-12-06|
    DE202006019887U1|2007-07-26|
    KR20070100368A|2007-10-10|
    WO2006077212A1|2006-07-27|
    BRPI0606247A2|2009-06-09|
    KR20210131450A|2021-11-02|
    KR20080106991A|2008-12-09|
    CN101106996A|2008-01-16|
    AP2249A|2011-07-18|
    DK200700207U3|2007-09-28|
    DE602006009899D1|2009-12-03|
    EA200701541A1|2008-02-28|
    RS51069B|2010-10-31|
    EA013544B1|2010-06-30|
    US20150190393A1|2015-07-09|
    PT1838318E|2009-12-15|
    NO20074174L|2007-10-17|
    AT446092T|2009-11-15|
    IL184530A|2015-01-29|
    KR20200128451A|2020-11-12|
    AP2007004057A0|2007-08-31|
    KR20120089710A|2012-08-13|
    US9271974B2|2016-03-01|
    ZA200705231B|2008-06-25|
    AR052880A1|2007-04-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5656295A|1991-11-27|1997-08-12|Euro-Celtique, S.A.|Controlled release oxycodone compositions|
    US5968551A|1991-12-24|1999-10-19|Purdue Pharma L.P.|Orally administrable opioid formulations having extended duration of effect|
    US5958459A|1991-12-24|1999-09-28|Purdue Pharma L.P.|Opioid formulations having extended controlled released|
    IL110014A|1993-07-01|1999-11-30|Euro Celtique Sa|Solid controlled-release oral dosage forms of opioid analgesics|
    US5478577A|1993-11-23|1995-12-26|Euroceltique, S.A.|Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level|
    US5965161A|1994-11-04|1999-10-12|Euro-Celtique, S.A.|Extruded multi-particulates|
    CA2250187A1|1996-03-25|1997-10-02|Eli Lilly And Company|Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain|
    CA2601289C|2001-05-02|2011-04-19|Euro-Celtique, S.A.|Once-a-day oxycodone formulations|
    US6992193B2|2003-06-10|2006-01-31|Adolor Corporation|Sulfonylamino phenylacetamide derivatives and methods of their use|UA94244C2|2005-11-14|2011-04-26|Ринат Нейросаенз Корп.|Antagonist antibody directed against calcitonin gene-related peptide and pharmaceutical composition comprising the same|
    AU2008258596B2|2007-06-04|2013-02-14|Egalet Ltd|Controlled release pharmaceutical compositions for prolonged effect|
    KR101304150B1|2008-03-04|2013-09-05|라브리스 바이올로직스 인코포레이티드|Methods of treating chronic pain|
    EP2393484A1|2009-02-06|2011-12-14|Egalet Ltd.|Immediate release composition resistant to abuse by intake of alcohol|
    NZ603579A|2009-06-24|2014-02-28|Egalet Ltd|Controlled release formulations|
    CN102740884A|2009-08-28|2012-10-17|瑞纳神经科学公司|Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide|
    KR102128628B1|2011-05-20|2020-06-30|앨더바이오 홀딩스 엘엘씨|Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea|
    CN107827982B|2011-05-20|2021-07-06|H.伦德贝克公司|Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or aversion to light in a subject in need thereof|
    TWI685505B|2011-05-20|2020-02-21|美商艾爾德生物控股有限責任公司|Anti-cgrp compositions and use thereof|
    PE20161439A1|2014-03-21|2017-01-26|Teva Pharmaceuticals Int Gmbh|ANTIBODIES ANTAGONISTS DIRECTED AGAINST THE PEPTIDE RELATED TO THE CALCITONIN GENE AND METHODS USING THE SAME|
    US10556945B2|2014-03-21|2020-02-11|Teva Pharmaceuticals International Gmbh|Antagonist antibodies directed against calcitonin gene-related peptide and methods using same|
    CN109952314A|2016-09-23|2019-06-28|泰瓦制药国际有限公司|Treat intractable migraine|
    AU2019383389A1|2018-11-19|2021-05-06|Jazz Pharmaceuticals Ireland Limited|Alcohol-resistant drug formulations|
    法律状态:
    2016-01-22| UUP| Utility model expired|Expiry date: 20160117 |
    优先权:
    申请号 | 申请日 | 专利标题
    US64549005P| true| 2005-01-18|2005-01-18|
    [返回顶部]